Abstract: This disclosure provides streptavidin monomers that bind biotin with high affinity and which possess slow dissociation rates. The disclosure also provides methods of making and using those monomers.

Abstract: A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described, are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment.

Abstract: A method for detecting biomaterial by means of a dye having a linear upconversion fluorescent property is provided. The method includes the steps of: i) preparing a fluorophore having a linear upconversion fluorescent property; ii) reacting the fluorophore and biomaterial to obtain a reaction complex thereof; iii) exciting the reaction complex by means of a light source having a longer wavelength than the maximum light-emitting wavelength of the fluorophore; and iv) detecting and measuring the light-emitting signal having a shorter wavelength than the wavelength of the excited light emitted from the excited reaction complex. A system and a kit for detecting biomaterial using a dye having a linear upconversion fluorescent property are also provided.

Abstract: Methods and apparatus for performing high energy atomic layer etching are provided herein. Methods include providing a substrate having a material to be etched, exposing a surface of the material to a modification gas to modify the surface and form a modified surface, and exposing the modified surface to an energetic particle to preferentially remove the modified surface relative to an underlying unmodified surface where the energetic particle has an ion energy sufficient to overcome an average surface binding energy of the underlying unmodified surface. The energy of the energetic particle used is very high; in some cases, the power applied to a bias used when exposing the modified surface to the energetic particle is at least 150 eV.

Abstract: A composite material is provided including a polymer matrix and undercooled liquid metallic core-shell particles disposed in the matrix, wherein the particles each have an outer shell and a liquid metallic material as a core contained within the outer shell. The outer shell is frangible such that the liquid metallic material is released from at least some of the particles in response to a mechanical load applied to the composite and solidifies in-situ in the polymer matrix. As a result, the composite material can be self-strengthening and self-healing and can be reconfigurable in shape at ambient temperature.

Abstract: A product design and process design device includes: a storage unit that stores design specification information containing the tolerance of a dimensional variation at any site of an assembly product, part dimension error information, assembly facility error information, assembly tolerance information, the part dimension error information, and the assembly facility error information, part manufacturing cost information, and facility investment cost information with respect to the assembly facility error information; a tolerance distribution processing unit that uses the assembly tolerance information to generate proposed tolerance distributions that differ in distributional combination with respect to each error, and calculates part manufacturing costs and facility investment costs; a facility planning processing unit that determines a proposed tolerance distribution, with, as an evaluation index, total production costs respectively including the sums of the part manufacturing costs and the facility investmen

Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and/or serine.

Abstract: Aqueous dispersions of artificially synthesized, mussel-inspired polydopamine nanoparticles were inkjet printed on flexible polyethylene terephthalate (PET) substrates. Narrow line patterns (4 ?m in width) of polydopamine resulted due to evaporatively driven transport (coffee ring effect). The printed patterns were metallized via a site-selective Cu electroless plating process at a controlled temperature (30° C.) for varied bath times. The lowest electrical resistivity value of the plated Cu lines was about 6 times greater than the bulk resistivity of Cu. This process presents an industrially viable way to fabricate Cu conductive fine patterns for flexible electronics at low temperature, and low cost.

Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.

Abstract: A computer-implemented method for domain analysis comprises: obtaining, by a computing device, a domain; and inputting, by the computing device, the obtained domain to a trained detection model to determine if the obtained domain was generated by one or more domain generation algorithms. The detection model comprises a neural network model, a n-gram-based machine learning model, and an ensemble layer. Inputting the obtained domain to the detection model comprises inputting the obtained domain to each of the neural network model and the n-gram-based machine learning model. The neural network model and the n-gram-based machine learning model both output to the ensemble layer. The ensemble layer outputs a probability that the obtained domain was generated by the domain generation algorithms.

Abstract: The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.

Abstract: This disclosure describes various embodiments for resource optimization in a vehicle. In an embodiment, a system for resource optimization in a vehicle is described. The system may comprise a memory; a processor coupled to the memory; and a resource optimization module. The resource optimization module may be configured to: monitor usage of local computing resources of the vehicle, the local computing resources comprising the processor and available bandwidth of a transmission medium; determine an availability of the local computing resources; evaluate data captured by one or more sensors of the vehicle; and determine whether to process the data locally or remotely based, at least in part, on the availability of the local computing resources and the data captured by the one or more sensors.

Abstract: In order to address a conventional problem that video signal processing in consideration of system features has not been performed, a video signal processing apparatus includes: a system feature accepting unit that accepts one or at least two system features from when an image is acquired to when an image is output; an input image accepting unit that accepts an input image; a conversion processing unit that performs conversion processing that acquires an output image from the input image, using the system features; and an output unit that outputs the output image acquired by the conversion processing unit. Accordingly, it is possible to perform video signal processing in consideration of system features.

Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.

Abstract: A system and methods for reducing the operating temperature of a solid state pumping system for lifting liquids from a wellbore. The pumping system and methods utilizing a solid state electrical actuator system. The cooling systems and methods including a heat sink for cooling the solid state actuator. The heat sink comprising at least one of; (i) a dielectric oil bath, (ii) a thermoelectric cooling element, (iii) an aperture within the at least one solid state actuator for conveying a cooling fluid through the aperture, and (iv) combinations thereof. The pumping system including and an electrical power source for powering the solid state pump.

Abstract: Provided herein is a three-dimensional co-culture of adipocytes and macrophages, wherein, in a hydrogel scaffold containing adipocytes and macrophages, the adipocytes and the macrophages are co-cultured to form a fat-like tissue, which can be then utilized in the studies and medicine development for treating metastatic diseases associated with adipose tissue.

Abstract: Fuel compositions for advanced combustion engines that include a naphtha boiling range portion are provided, where the fuel compositions can have a reduced ignition delay and/or an improved derived cetane number. The improved combustion properties can be achieved by adding a portion of a light naphtha (boiling range) composition to a heavy naphtha boiling range composition. The addition of up to about 10 vol % of a light naphtha composition to a heavy naphtha composition can result in a mixture having a reduced ignition delay relative to the heavy naphtha composition.

Abstract: Protein complex variants, compositions, and methods of use thereof are provided. The protein complex variant includes a cholera toxin B subunit variant having one or more modifications thereto. The method of use thereof includes treating a disease by administering an effective amount of a composition including a cholera toxin B subunit variant to a subject in need thereof.